359586-17-7

Upstream product

• 359585-97-0 tert-butyl 2-methyl-4-{[(trifluoromethyl)sulfonyl]oxy}-1H-indole-1-carboxylate 
• 359585-98-1 tert-butyl 2-methyl-4-[(trimethylsilyl)ethynyl]-1H-indole-1-carboxylate 
• 359586-15-5 benzyl (2-methyl-1H-indol-4-yl)acetate 
• 359585-96-9 2-methyl-1H-indol-4-yl trifluoromethanesulfonate 
• 35320-67-3 4-hydroxy-2-methyl-1H-indole 
• 359586-16-6 benzyl {1-[4-(acetoxy)benzoyl]-2-methyl-1H-indol-4-yl}acetate 
• 359585-99-2 1-tert-butoxycarbonyl-2-methyl-1H-indol-4-yl acetic acid 
• 359586-00-8 2-methylindole-4-acetic acid 

Downstream Products

• 756479-02-4 benzyl {2-methyl-1-[4-(2-phenylethoxy)benzoyl]-1H-indol-4-yl}acetate 
• 756478-92-9 benzyl [1-(4-butoxybenzoyl)-2-methyl-1H-indol-4-yl]acetate 
• 502433-34-3 1-(4-((2S)-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-2-ylmethoxy)benzoyl)-2-methyl-1H-indol-4-yl acetic acid benzyl ester 

Relevant academic research and scientific papers

Discovery of orally active prostaglandin D2 receptor antagonists

Discovery process of a new PGD2 receptor antagonists 3i is reported. A series of N-(p-alkoxy)benzoyl-2-methylindole-4-acetic acids were synthesized and evaluated for prostaglandin D2 (DP) receptor affinity and antagonist activity. So

INDOLE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT

Indole derivatives represented by formula (I) ???wherein all symbols represent the same as that in specification), production methods thereof, and DP receptor antagonist comprising them as active ingredients. Since the compounds of formula (I) binds and antagonizes to DP receptor, they are useful for the prevention and/or treatment against allergic diseases, diseases accompanied with itching, secondary diseases generated by behaviors caused by itching, inflammation, chronic obstructive pulmonary disease, ischemic reperfusion disorder, cerebrovascular disorder, pleuritis complicated by rheumatoid arthritis, ulcerative colitis.

Indole derivatives, process for preparation of the same and use thereof

Indole derivatives represented by formula (I): (wherein all symbols are described in the description), a process for the preparation of the same and a DP receptor antagonist comprising it as an active ingredient. Since the compounds of formula (I) binds to and are antagonistic to a DP receptor, they are useful in for the prevention and/or treatment of diseases, for example, allergic diseases (allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma, food allergy, etc., systemic mastocytosis; disorders due to systemic mastocyte activation, anaphylactic shock, bronchoconstriction, urticaria, eczema, etc.), diseases accompanied with itching (atopic dermatitis, urticaria, etc.), secondary diseases caused by behaviors (scratching behaviors, beating, etc.) (cataract, retinal detachment, inflammation, infection, sleep disorder, etc.), inflammation, chronic obstructive pulmonary disease, ischemic reperfusion disorder, cerebrovascular disorder, pleuritis complicated by rheumatoid arthritis, ulcerative colitis, and the like.